Adverse events and serious adverse events
death, anaphylactic allergic reaction, dyspnea, humerus fracture, trauma
ADVERSE EVENTS, DISEASE PROGRESSION
There were three serious adverse events where patients presented progressive dyspnea, requiring admission at the emergency department. Of these, one patient experienced further disease progression leading to death approximately 1 month after therapy. One patient developed a severe anaphylactic allergic reaction after the first 100 mg infusion of rituximab, resulting in discontinuation of rituximab treatment. One patient presented with trauma and subsequent humerus fracture, unrelated to rituximab therapy.